News Releases

Date Title
10/17/2012 Summary ToggleEnanta’s Lead Hepatitis C Compound ABT-450 Advances into a Phase 3 Clinical Trial through its Collaboration with Abbott
09/19/2012 Summary ToggleFierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
04/19/2012 Summary ToggleAbbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
04/19/2012 Summary ToggleAbbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
04/04/2012 Summary ToggleEnanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
02/21/2012 Summary ToggleEnanta Enters into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
10/13/2011 Summary ToggleEnanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic
09/26/2011 Summary ToggleEnanta’s Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover’s Top 10 Infectious Disease Projects to Watch
04/04/2011 Summary ToggleAbbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
11/01/2010 Summary ToggleAbbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/R for Treatment of Hepatitis C